Home - Microbiome Times Magazine

Fecal transplant turns cancer immunotherapy non-responders into responders

February 10, 2021

Video Credits: UNIVERSITY OF PITTSBURGH Researchers at UPMC Hillman Cancer Center and the National Cancer Institute (NCI) demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy–which […]

Why microbiota samples should be collected in all clinical trials?

January 26, 2021

In recent years, the understanding of how the microbiome and human health are linked has expanded considerably. We believe the rise in this understanding and the growing interest towards our microbiome research-focused Health for Life […]

Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19

January 20, 2021

Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced positive interim results from the K031 non-IND controlled clinical study evaluating outpatients with mild to moderate COVID-19 disease. Patients in this non-IND clinical study were randomized within 48 […]

Investigating the removal of dry biofilm with probiotic cleansers

February 9, 2021

A CONCEPT known as dry biofilms has emerged over the past few years and they have shown to frequently harbour potentially infectious organisms, just like the ones present in Hospital Acquired Infections (HAIs). However, as […]

MIND and Mediterranean diets associated with later onset of Parkinson’s disease

February 5, 2021

A new study from UBC researchers suggests a strong correlation between following the MIND and Mediterranean diets and later onset of Parkinson’s disease (PD). While researchers have long known of neuroprotective effects of the MIND […]

Lactobacillus manipulates bile acids to create favorable gut environment

February 4, 2021

New research from North Carolina State University reveals that probiotic Lactobacillus bacteria use enzymes situationally to manipulate bile acids and promote their own survival in the gut. These findings further elucidate the complicated relationship between […]

Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132

February 3, 2021

Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to prevent the life-threatening effects antibiotics have on the gut microbiome of cancer patients, announced today that it received approval to start enrolling patients in a […]